Over the past five years, Grindeks, by investing more than 32 million lats, has made strategic investments in the business infrastructure development, in the establishment of new active pharmaceutical ingredients and final dosage form production units and other important projects. Thus, a world class pharmaceutical manufacturing infrastructure has been developed, which is an important advantage in the tough competition.

 

In his presentation, Grindeks Chief Finance and Administrative Officer Vadims Rabša will inform on the market situation of final dosage forms and active pharmaceutical ingredients and will talk about Grindeks strategy of original products and generics and business development prospects in existing and new markets.

Grindeks strategy (650 KB)

Grindeks Chief Finance and Administrative Officer Vadims Rabša: “We have all the prerequisites – a modern infrastructure, abundant knowledge and extensive experience in the pharmaceutical business. Right now, in the pharmaceutical industry competition is becoming increasingly fierce. Grindeks will more and more purposefully use its potential. Our main task is to investigate the patient and client needs and to create offer by expanding the product range.”

 

“Nasdaq OMX Vilnius” annually organizes a conference for investors, which brings together the representatives of the Baltic States companies and wide range of investors.

About Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently Grindeks produces 22 active pharmaceutical ingredients.

Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S. In 2010 the Ministry of Economics of Republic of Latvia and the Investment and Development Agency of Latvia awarded Grindeks as the most export potential company of Latvia.

During the last years the company realized many considerable investment projects in purpose to increase production capacity and develop infrastructure and invested 32.7 million lats within five years.

JSC Grindeks shares are listed on the Official List of “Nasdaq OMX Riga”. Major shareholders of JSC Grindeks are Kirovs Lipmans – 33.29%, Anna Lipmane – 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda Banken” – 10.94%, “Swedbank” AS Clients Account – 8.28%.

 

Further information: 

Laila Kļaviņa
Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
laila.klavina@grindeks.lv